Early detection of Alzheimer’s disease (AD) can improve treatment outcomes, but current testing methods still have limitations. Researchers have long relied on cerebrospinal fluid (CSF) biomarkers and ...

For much of the past century, Alzheimer's disease has been one of medicine's most daunting frontiers—biologically complex, ...

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment BILLERICA, Mass.--(BUSINESS WIRE)--Lucent ...

Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...

Alzheimer's pathology was common in other dementias. An Alzheimer's biomarker profile was seen in unspecified dementia, Parkinson's dementia, and frontotemporal dementia. Biomarkers indicating ...

Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

TORONTO — An expert panel convened by the Alzheimer’s Association has released the first clinical guidelines to help clinicians choose the most appropriate blood-based biomarker (BBM) test to aid in ...